Bridgeway Capital Management, LLC Mersana Therapeutics, Inc. Transaction History

Bridgeway Capital Management, LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$2.0 - $4.45 $486,400 - $1.08 Million	243,200 Added 104.69%	475,500 $955,000
Q4 2023 Feb 14, 2024	SELL	$1.11 - $2.34 $387,834 - $817,596	-349,400 Reduced 60.07%	232,300 $538,000
Q3 2023 Nov 14, 2023	BUY	$1.06 - $3.91 $616,602 - $2.27 Million	581,700 New	581,700 $738,000
Q1 2020 May 15, 2020	SELL	$4.41 - $9.28 $702,954 - $1.48 Million	-159,400 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$1.45 - $6.73 $67,570 - $313,618	46,600 Added 41.31%	159,400 $913,000
Q3 2019 Nov 14, 2019	BUY	$1.54 - $4.2 $97,020 - $264,600	63,000 Added 126.51%	112,800 $178,000
Q1 2019 May 15, 2019	BUY	$3.51 - $7.3 $174,798 - $363,540	49,800 New	49,800 $262,000

121

116M

233K

457K

Ticker MRSN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 97,169,296
Market Cap $198M
Description
Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet need. It develops XMT-1592, a Dolasynthen ADC targeting NaPi2b-expressing tumor cells, which is in phase I clinical trial for the treatment of ovarian cancer and NSCLC adenocarcinoma. The company also dev...

Get notified when there are updates to the investment portfolio of Bridgeway Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Bridgeway Capital Management, LLC with notifications on news.